Last reviewed 2026-04-19 · How we verify

LY4292009

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Phase 1 active Small molecule

At a glance

Generic name	LY4292009
Sponsor	Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LY4292009 CI brief — competitive landscape report
LY4292009 updates RSS · CI watch RSS
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) portfolio CI